Abstract

Loeys-Dietz syndrome (LDS) is a connective tissue disorder that is characterized by skeletal abnormalities, craniofacial malformations, and a high predisposition for aortic aneurysm. In this issue of the JCI, Gallo et al. developed transgenic mouse strains harboring missense mutations in the genes encoding type I or II TGF-β receptors. These mice exhibited several LDS-associated phenotypes. Despite being functionally defective, the mutated receptors enhanced TGF-β signaling in vivo, inferred by detection of increased levels of phosphorylated Smad2. Aortic aneurysms in these LDS mice were ablated by treatment with the Ang II type 1 (AT1) receptor antagonist losartan. The results from this study will foster further interest into the potential therapeutic implications of AT1 receptor antagonists.

Document Type

Commentary

Publication Date

1-2-2014

Notes/Citation Information

Published in The Journal of Clinical Investigation, v. 124, issue 1, p. 79-81.

Copyright © 2014, American Society for Clinical Investigation

The copyright holder has granted permission for posting the article here.

Digital Object Identifier (DOI)

http://dx.doi.org/10.1172/JCI73906

Share

COinS